Stockscreener 앱 받기
217.81
1.06%
2.3113
전일 마감가:
$215.50
열려 있는:
$216.14
하루 거래량:
73,886
Relative Volume:
0.07
시가총액:
$32.18B
수익:
$9.60B
순이익/손실:
$1.37B
주가수익비율:
23.37
EPS:
9.3182
순현금흐름:
$2.32B
1주 성능:
+0.19%
1개월 성능:
+0.46%
6개월 성능:
+20.01%
1년 성능:
+52.83%
1일 변동 폭
$214.59
$218.72
1주일 범위
$213.54
$220.17
52주 변동 폭
$135.39
$225.80
Biogen Inc Stock (BIIB) Company Profile
명칭
Biogen Inc
전화
(781) 464-2000
주소
225 BINNEY STREET, CAMBRIDGE, MA
Compare BIIB vs LLY, JNJ, ABBV, MRK, NVS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
217.78 | 32.08B | 9.60B | 1.37B | 2.32B | 9.3182 |
LLY
Lilly Eli Co
|
1,166.37 | 994.49B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
271.78 | 640.02B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
265.04 | 454.36B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
148.20 | 355.10B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
141.97 | 260.70B | 54.66B | 13.58B | 16.05B | 7.0171 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-22 | 업그레이드 | UBS | Neutral → Buy |
| 2026-04-20 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2026-04-14 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2026-02-20 | 개시 | Barclays | Equal Weight |
| 2026-02-09 | 재확인 | H.C. Wainwright | Buy |
| 2026-01-07 | 재개 | UBS | Neutral |
| 2025-12-10 | 다운그레이드 | HSBC Securities | Hold → Reduce |
| 2025-11-06 | 업그레이드 | Stifel | Hold → Buy |
| 2025-09-25 | 개시 | Jefferies | Buy |
| 2025-07-21 | 재개 | Truist | Hold |
| 2025-04-28 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2025-04-04 | 다운그레이드 | Argus | Buy → Hold |
| 2025-02-11 | 개시 | Bernstein | Mkt Perform |
| 2025-01-02 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | 다운그레이드 | Stifel | Buy → Hold |
| 2024-12-10 | 재개 | BofA Securities | Neutral |
| 2024-12-09 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-11-18 | 다운그레이드 | Needham | Buy → Hold |
| 2024-11-15 | 개시 | Wolfe Research | Peer Perform |
| 2024-11-14 | 개시 | Citigroup | Neutral |
| 2024-10-31 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | 재개 | Raymond James | Mkt Perform |
| 2024-02-14 | 재확인 | Needham | Buy |
| 2024-02-14 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-12-20 | 재개 | Cantor Fitzgerald | Overweight |
| 2023-12-07 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | 개시 | HSBC Securities | Buy |
| 2023-07-27 | 개시 | Scotiabank | Sector Outperform |
| 2023-07-24 | 재확인 | UBS | Buy |
| 2023-05-01 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-04-17 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-10-13 | 업그레이드 | Stifel | Hold → Buy |
| 2022-10-07 | 업그레이드 | Argus | Hold → Buy |
| 2022-09-28 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | 업그레이드 | Mizuho | Neutral → Buy |
| 2022-09-28 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-03-03 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | 재확인 | Barclays | Equal Weight |
| 2022-02-04 | 재확인 | BofA Securities | Neutral |
| 2022-02-04 | 재확인 | Cowen | Outperform |
| 2022-02-04 | 재확인 | Morgan Stanley | Overweight |
| 2022-02-04 | 재확인 | Needham | Buy |
| 2022-02-04 | 재확인 | Oppenheimer | Outperform |
| 2022-02-04 | 재확인 | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | 재확인 | Robert W. Baird | Neutral |
| 2022-02-04 | 재확인 | Wedbush | Neutral |
| 2022-02-04 | 재확인 | Wells Fargo | Equal Weight |
| 2022-02-04 | 재확인 | Wolfe Research | Peer Perform |
| 2022-01-13 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-01-12 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | 재개 | Raymond James | Mkt Perform |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-12-06 | 개시 | Goldman | Neutral |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-09-23 | 개시 | Needham | Buy |
| 2021-06-18 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | 재확인 | Truist | Buy |
| 2021-06-11 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | 업그레이드 | UBS | Neutral → Buy |
| 2021-06-08 | 업그레이드 | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | 재확인 | Barclays | Equal Weight |
| 2021-06-08 | 업그레이드 | Citigroup | Sell → Neutral |
| 2021-06-08 | 재확인 | H.C. Wainwright | Buy |
| 2021-06-08 | 재확인 | Jefferies | Buy |
| 2021-06-08 | 재확인 | Morgan Stanley | Overweight |
| 2021-06-08 | 재확인 | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | 업그레이드 | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | 재확인 | Stifel | Buy |
| 2021-06-08 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2021-06-07 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2021-06-07 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | 다운그레이드 | DZ Bank | Buy → Hold |
| 2021-01-29 | 업그레이드 | Stifel | Hold → Buy |
| 2020-11-10 | 업그레이드 | DZ Bank | Hold → Buy |
| 2020-11-09 | 다운그레이드 | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2020-11-09 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2020-11-09 | 재확인 | H.C. Wainwright | Buy |
| 2020-11-04 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2020-11-04 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-11-04 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | 개시 | UBS | Neutral |
| 2020-07-27 | 업그레이드 | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2020-06-22 | 재확인 | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2020-04-23 | 다운그레이드 | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | 개시 | Wolfe Research | Peer Perform |
| 2020-02-27 | 개시 | Barclays | Overweight |
| 2020-01-27 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
모두보기
Biogen Inc 주식(BIIB)의 최신 뉴스
Biogen Sees Pivotal Pipeline Moment as It Expands Beyond Neurology - Yahoo Finance
Biogen (BIIB) Sees Canada Back LEQEMBI As Fair Value Stays In Focus - simplywall.st
Alzheimer’s Disease Market Trends, Innovation, and Future Growth Outlook to 2036 – DelveInsight | Alpha Cognition, Biogen, Eisai, Eli Lilly, Otsuka Pharma, Lundbeck, Suven Life Sciences, Roche - Barchart.com
Multiple Sclerosis Market Outlook 2036: Growth Trends, Competitive Landscape, and Future Opportunities by 2034 – DelveInsight | Biogen, Immune Response BioPharma, ImCyse, Atara Bio, Emerald Health - Barchart.com
Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch
BIIB Maintained by HSBC -- Price Target Raised to $175 - GuruFocus
Biogen Inc. stock gains on fresh analyst upgrades and strong Q2 figures - ad-hoc-news.de
Stifel reiterates Biogen stock rating on immunology pipeline - investing.com
Stifel reiterates Biogen stock rating on immunology pipeline By Investing.com - Investing.com Canada
Can Biogen (NASDAQ:BIIB) Stay Resilient As Inflation Rises? - Kalkine Media
Biogen at Wells Fargo healthcare conference: growth bets widen By Investing.com - Investing.com Canada
Biogen Inc. at Wells Fargo Healthcare Conference Transcript - GuruFocus
Learn Why The Bull Case For Biogen Stock Could Change Following Canada Reimbursement Backing - simplywall.st
Monoclonal Antibodies Market to Grow at 11.01% CAGR, Reaching USD 791.28 Billion by 2035 – SNS Insider - GlobeNewswire Inc.
Biogen Inc (BIIB) Shares Fall 3.8% -- What GF Score of 73 Tells Investors - GuruFocus
Biogen Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers - Reuters
Biogen Must Face Pharmacies' MS Drug Monopoly Suit - Law360
(BIIB) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Biogen stock heads into the open without fresh price data - ad-hoc-news.de
Biogen Inc. (BIIB) Investor Outlook: Navigating Growth in the Healthcare Sector with a Potential 7.26% Upside - DirectorsTalk Interviews
Biogen Inc at Bank of America Global Healthcare Conference Transcript - GuruFocus
Biogen Inc. stock holds near 12 month high on steady Q1 2026 growth - ad-hoc-news.de
BIIB Stock Price Prediction 2026-2027 | Biogen Forecast - 24/7 Wall St.
Biogen Inc. (BIIB) Peer Comparison – Compare with Others - Value Research
Eisai, Biogen Secure China's Nod for Self-Injection Version of Leqembi - marketscreener.com
Biogen (BIIB), Why Is Its Latest Update Drawing Fresh Attention? - simplywall.st
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC) - Biogen
Biogen Inc. - Via Ritzau
Biogen (BIIB) awards 7,405 stock units to its top lawyer - Stock Titan
Biogen Is Repositioning Its Portfolio To Partly Offset Ongoing Revenue Declines - Morningstar
Piper Sandler raises Biogen stock price target on pipeline outlook - Investing.com
Eisai, Biogen Win China Approval for Leqembi Self-Injection - International Business Times
Price cut becomes the price of coverage for Alzheimer's drug lecanemab - Benefits and Pensions Monitor
Biogen (BIIB) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $BIIB - MarketBeat
Biogen Inc. (BIIB) Key Financial Ratios – Valuation, Profitability & More - Value Research
Eisai and Biogen Announce China Approval of LEQEMBI SC-AI for Initiation Treatment of Early Alzheimer’s Disease - Quiver Quantitative
LEQEMBI® (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer’s Disease Approved in China - Biogen
Biogen (BIIB) Stock Could Be 48% Below Fair Value On New Dravet Data - Yahoo Finance
How Biogen’s (BIIB) At-Home LEQEMBI Injections Could Reframe the Alzheimer’s Treatment Investment Story - simplywall.st
Biogen Inc (BIIB) Shares Surge 3.1% -- What GF Score of 73 Tells Investors - GuruFocus
Biogen gains as pipeline updates and fresh Street target hikes buoy sentiment - Quiver Quantitative
Biogen stock hits 52-week high at 222.86 USD By Investing.com - Investing.com Canada
Biogen stock hits 52-week high at 222.86 USD - Investing.com
A potential seizure treatment will be presented Sept. 9 by Stoke Therapeutics - Stock Titan
Biogen’s (BIIB) Immunology Bet Meets A Pricier Balance Sheet - Yahoo Finance
BIIB | Biogen Inc. Common Stock FinancialsRevenue Breakdown - Quiver Quantitative
Stoke, Biogen present 4-year zorevunersen data for Dravet syndrome - Investing.com
Eisai and Biogen Announce Canada’s Drug Agency Final Recommendation Supporting Public Reimbursement of LEQEMBI for Eligible Early Alzheimer’s Disease Patients - Quiver Quantitative
Canada’s Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI® (lecanemab) for Early Alzheimer’s Disease - Biogen
Final CDA-AMC Recommendation Brings Canadians with Early-Stage Alzheimer's Disease One Step Closer to Accessing LEQEMBI® (lecanemab) - PR Newswire Canada
Biogen Inc (BIIB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Biogen Inc 주식 (BIIB) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Minor Lloyd | Director |
Aug 04 '26 |
Sale |
200.96 |
593 |
119,169 |
2,689 |
0.25%
0.62%
자본화:
|
볼륨(24시간):